Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Actual pricing could be higher or lower
Potential pancreatitis risk : As with other GLP-1-based therapies, there is a theoretical concern regarding pancreatitis, though causality has not been firmly established in trials to date
For example, several studies report that elevated levels of blood-based markers such as fibrinogen are positively associated with the intensity of depressive symptoms
Apart from WEGOVY, SAXENDA , another Novo Nordisk weight loss drug, is also approved in the US for obesity
US$ 23.18
US$ 22.05
US$ 28.13
US$ 24.85
